secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001193125-22-005120
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences reports $210M cash, advances DMD gene therapies; names Ian Smith Executive Chair
--------------------------------------------------------------------------------

- Preliminary, unaudited cash and investments of ~$210M as of Dec 31, 2021.
- Ninth patient dosed in IGNITE DMD Phase I/II trial for SGT-001 in Nov 2021 using second-gen manufacturing.
- Plans to share additional SGT-001 expression, functional, pulmonary data in H1 2022.
- SGT-003 IND-enabling studies in 2022; IND filing targeted early 2023.
- Board Chair Ian F. Smith appointed Executive Chair effective Jan 10, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522005120/0001193125-22-005120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522005120/d289427d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-005120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer